163622-50-2

Basic information

• Product Name: 4-AMino-5-iodopyrrolo[2,3-d]pyriMidine
• Synonyms: 4-AMino-5-iodopyrrolo[2,3-d]pyriMidine
• CAS NO: 163622-50-2
• Molecular Formula: C₆H₅IN₄
• Molecular Weight: 260.03517
• Mol File: 163622-50-2.mol

Chemical Properties

• Boiling Point: 254.0±50.0 °C(Predicted)
• Appearance: /
• Density: 2.58±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 11.57±0.20(Predicted)
• CAS DataBase Reference: 4-AMino-5-iodopyrrolo[2,3-d]pyriMidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-AMino-5-iodopyrrolo[2,3-d]pyriMidine(163622-50-2)
• EPA Substance Registry System: 4-AMino-5-iodopyrrolo[2,3-d]pyriMidine(163622-50-2)

Safety Data

• Hazardous Substances Data: 163622-50-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
4-Amino-5-iodopyrrolo[2,3-d]pyrimidine is used as a compound of interest for its potential pharmaceutical applications. Its unique structure, which includes a pyrrole and pyrimidine ring along with an amino group and iodine atom, suggests that it may have properties that could be harnessed in the development of new drugs or therapeutic agents.
Used in Medical Research:
In the field of medical research, 4-Amino-5-iodopyrrolo[2,3-d]pyrimidine is utilized as a subject for investigation due to its potential implications in the discovery of new treatments or understanding of disease mechanisms. 4-AMino-5-iodopyrrolo[2,3-d]pyriMidine's structure and properties may provide insights into the development of novel therapeutic strategies or contribute to the advancement of existing ones.

Upstream product

• 1500-85-2 7-deazaadenine 
• 3680-71-5 Allopurinol 

Downstream Products

• 1616484-36-6 ethyl 2-(4-amino-5-(1-benzyl-1H-1,2,3-triazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)acetate 
• 1616484-44-6 2-(4-amino-5-(1-benzyl-1H-1,2,3-triazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)acetic acid 
• 1616484-38-8 C₁₈H₁₇N₇O₂ 
• 1603845-32-4 TX₁-85-1 
• 1603845-25-5 1-(4-(4-(4-amino-3-(4-fluoro-3-nitrophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)cyclohexyl)piperazin-1-yl)ethanone 
• 1603845-26-6 1-(4-(4-(4-amino-3-(3-nitro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)cyclohexyl)piperazin-1-yl)ethanone 
• 1603845-34-6 C₂₁H₂₄FN₇O₄ 
• 1603845-35-7 C₂₇H₂₉N₇O₅ 
• 1603845-36-8 3-(3-nitro-4-phenoxyphenyl)-1-(piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1603845-37-9 tert-butyl (2-(4-(4-amino-3-(3-nitro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)ethyl)carbamate 
• 1603845-38-0 C₂₄H₂₆N₈O₃ 
• 1603845-39-1 (R)-4-(adamantan-1-yl)-N-(2-(4-(4-amino-3-(3-nitro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)ethyl)-2-methylbutanamide 
• 1603845-40-4 C₄₉H₆₄N₈O₈ 
• 1603845-41-5 C₄₉H₆₆N₈O₆ 

Relevant articles and documents

Identification of Pyrrolo[2,3-d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia

A series of pyrrolo[2,3-d]pyrimidine derivatives were prepared and optimized for cytotoxic activities against FLT3-ITD mutant cancer cells. Among them, compound 9u possessed nanomolar FLT3 inhibitory activities and subnanomolar inhibitory activities against MV4-11 and Molm-13 cells. It also showed excellent inhibitory activities in FLT3-ITD-D835V and FLT3-ITD-F691L cells which were resistant to quizartinib. Furthermore, 9u exhibited over 40-fold selectivity toward FLT3 relative to c-Kit kinase, which might reduce myelosuppression toxicity. Cellular assays demonstrated that 9u inhibited phosphorylated FLT3 and downstream signaling factors and also induced cell cycle arrest in the G0/G1 stage and apoptosis in MV4-11 and Molm-13 cells. Oral administration of 9u at 10 mg/kg could achieve rapid tumor extinction in the MV4-11 xenograft model and significantly inhibit the tumor growth in the MOLM-13 xenograft model with a tumor growth inhibitory rate of 96% without obvious toxicity. Additionally, 9u demonstrated high bioavailability (F = 59.5%) and suitable eliminated half-life time (T1/2 = 2.06 h), suggesting that 9u may be a potent candidate for treating acute myelogenous leukemia.

HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES

The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be kinase (e.g., HCK, BTK, LYN, BLK, FRK) inhibitors. Also provided are pharmaceutical compositions and kits including the provided compounds. Further provided are methods of using the provided compounds, pharmaceutical compositions, and kits (e.g., for treating diseases (e.g., proliferative diseases) in a subject in need thereof).

Method for synthesizing 4 -chloropyrropyrimidine compound (by machine translation)

The invention relates to a synthesis method of 4 -lopyrrolopyrimidine compound, which comprises the following steps: mixing 4 -hydroxypyrrolopyrimidine, phosphorus oxychloride and organic base in a temperature range &at;timetimewise and removing excess ethanol to obtain 3 - 7-amino-4 -iodopyrrolopyrimidine; thirdly, dissolving the product 4 -amino-4 -methyl pyrrolopyrimidine in DMF at room temperature and then drying and concentrating 4 -aminopyrrolopyridine. 4 -aminopyrimidine is dissolved in dichloromethane and then subjected to a heat preservation reaction to get -5 -aminopyrrolopyrimidine; and the mixture is dried to remove the solid insoluble matter and is dried and concentrated to yield 12 hours-aminopyrroyrimidine after the heat preservation reaction is carried out; and the solvent is evaporated to remove the solid insoluble matter and is dried and concentrated to remove the solid insoluble matter 4 -5 -7. (by machine translation)

4-aminopyrrolopyrimidine derivative and preparation method and application thereof

The invention relates to a 4-aminopyrrolopyrimidine derivative and a preparation method and application thereof, and belongs to the field of medicines. The invention provides a compound shown as a formula I or pharmaceutically acceptable salt thereof. The

4-amino-pyrimido azacyclo-phenylurea derivatives, and preparation method and application thereof

The invention belongs to the field of chemical medicines, and particularly relates to 4-amino-pyrimido azacyclo-phenylurea derivatives, and a preparation method and application thereof. The structuralformula of the 4-amino-pyrimido azacyclo-phenylurea derivatives is represented by formula I in the specification. In addition, the invention further provides the preparation method and the application of the 4-amino-pyrimido azacyclo-phenylurea derivativess. The 4-amino-pyrimido azacyclo-phenylurea derivative provided by the invention can be used as an FLT3 kinase inhibitor, have a good effect, and provide a new choice for preparing antitumor drugs.

Alkynyl (hetero) aromatic ring compound for inhibiting activity of protein tyrosine kinase

The present invention relates to an alkynyl (hetero) aromatic ring compound having protein tyrosine kinase inhibition effect, and a preparation method thereof, a pharmaceutical composition containingthe alkynyl (hetero) aromatic ring compound, and uses of

Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model

We herein report the structural optimization and structure-activity relationship studies of 5-(2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as a new class of receptor-interacting protein kinase 1 (RIPK1) inhibitors. Among all obtained RIPK1 inhibitors, 1-(5-{4-amino-7-ethyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2,3-dihydro-1H-indol-1-yl)-2-[3-(trifluoromethoxy)phenyl]ethan-1-one (22b) is the most active one. This compound potently inhibited RIPK1 with a binding affinity (KD) of 0.004 μM and an enzymatic IC50 value of 0.011 μM and also showed good kinase selectivity. It could efficiently protect cells from necroptosis and attenuate the necrotic cell death of vascular endothelial cells induced by tumor cells both in vitro and in vivo. Importantly, compound 22b exhibited excellent antimetastasis activity in the experimental B16 melanoma lung metastasis model. It also displayed favorable pharmacokinetic properties. Collectively, 22b could be a promising agent for preventing tumor metastasis.

THERAPEUTIC INHIBITORY COMPOUNDS

Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.

Synthesis and photophysical evaluation of new fluorescent 7-arylethynyl-7-deazaadenosine analogs

Three new fluorescent 7-deaza-2′-deoxyadenosine analogs were synthesized via the Sonogashira cross-coupling reaction of 7-iodo-7-deaza-2′-deoxyadenosine with 1-ethynylpyrene, 2-ethynyl-6-methoxynaphthalene, and 9-ethynylphenanthrene. The spectral properties of these analogs were evaluated in dioxane, EtOH, and H2O to determine their potential for use as environmentally sensitive fluorescent probes. All three analogs displayed large solvatofluorochromicity in H2O, relative to their emission wavelengths in dioxane or EtOH. Moreover, all three analogs exhibited microenvironmental sensitivity of their fluorescence emission intensity, being moderate to high quantum yields in dioxane and EtOH and significantly lower in H2O. Various attempts to perform domino cross-coupling and annuation reactions on 7-deaza-7-alkynyladenine derivatives to form a new fused tricyclic adenine analog were unsuccessful.

7H - pyrrolo [2, 3 - d] pyrimidine derivatives (by machine translation)

The invention of the formula (I) indicated by the 7H - pyrrolo [2, 3 - d] pyrimidine derivatives. The invention provides compound on the tumor cell has prominent inhibit function, can be used for the prevention and/or treatment of tumor-related disorders, particularly lung, and has a wide application. (by machine translation)